Proteolysis-concentrating on chimeras (PROTACs) and molecular glue degraders (MGDs) are essentially the most maturely produced TPD approaches. With this critique, we deal with the two preclinical experiments and clinical trials to provide a comprehensive summary of the safety and scientific performance of PROTACs and MGDs in hematologic malignancie